Pharmaceuticals
Pharmaceutical products are used to prevent, diagnose m88 casino review treat diseases, m88 casino review are subject to theDrug Administration Law of the People’s Republic of China, theImplementing Regulations of the Drug Administration Law of the People's Republic of China,m88 casino review other laws m88 casino review regulations. In recent years, to adapt to the rapid development of the pharmaceutical industry, the breadth m88 casino review intensity of drug regulatory reform in China has escalated dramatically, m88 casino review the pace of China’s integration with the international drug regulatory system has increased significantly.
JunHe’s dedicated team has years of experience serving the pharmaceutical industry. With an in-depth understm88 casino reviewing of the pharmaceutical industry, a broad client base m88 casino review a strong relationship with industry regulators, our services cover all aspects of drug research m88 casino review development, manufacturing, commercialization, marketing, use, post marketing surveillance, adverse event monitoring m88 casino review recall. Supported by other practice groups in JunHe, our team can provide a one-stop service for pharmaceutical enterprises in areas such as regulatory, corporate m88 casino review M&A, capital market, private equity/venture capital, intellectual property, compliance m88 casino review dispute resolution.
We can provide the following legal services in the pharmaceutical industry:
Regulatory.We provide regulatory legal services in relation to preclinical research, clinical trials, drug registration, m88 casino review GCP/GMP compliance for drug development m88 casino review manufacturing enterprises, m88 casino review can also advise on marketing, promotion, distribution, bidding m88 casino review tendering, adverse drug reaction monitoring, m88 casino review product recall. We design m88 casino review evaluate the optimal path for drug registration m88 casino review commercialization for our clients, in accordance with the latest drug review policies.
Pharmaceutical licensing transactions.We have participated in many complex transactions that have involved drugs that are in the R&D stage or have been marketed. We have first-hm88 casino review experience in cross-border co-development m88 casino review licensing transactions for drug products.
Pharmaceutical co-development m88 casino review commercial transactions.We have assisted many pharmaceutical companies in different types of cooperative transactions with their business partners, leveraging their respective strengths through various structure m88 casino review cooperation models, including joint ventures, co-developments m88 casino review promotional collaborations, to accelerate the commercial value of their products.
Pharmaceutical M&A transactions.We have assisted many multinational pharmaceutical, biopharma m88 casino review biotech companies in their equity m88 casino review asset merger m88 casino review acquisition transactions, helping them to integrate their supply chain m88 casino review expm88 casino review their business, m88 casino review to achieve rapid growth through M&A.
Private equity m88 casino review capital markets.Our clients include well-known investment institutions committed to the pharmaceutical sector, such as Sequoia, Qiming, Warburg Pincus, CITIC Capital m88 casino review Ping An. We have also assisted many leading biotech companies, as well as listed companies who have achieved outstm88 casino reviewing results in the pharmaceutical industry. We have participated in the listing of companies such as BeiGene, Shanghai Pharma, Xinhua Pharmaceutical m88 casino review NT Pharma.
Intellectual property.With a professional team of lawyers from our Silicon Valley, Shanghai, Beijing m88 casino review Guangzhou offices, we can provide trans-regional, comprehensive m88 casino review professional services for numerous innovative drug research m88 casino review development companies across the country. We have had exceptional results in cases involving patent protection (including patent applications) m88 casino review dispute resolution involving intellectual property.
Compliance.Our compliance services cover drug regulatory compliance, anti-trust compliance, anti-commercial bribery compliance, privacy protection m88 casino review data security compliance, m88 casino review human genetic resources compliance in China. In addition to assisting clients in internal compliance investigations, we have vast experience in dealing with law enforcement actions by government agencies m88 casino review have established positive working relationships with law enforcement agencies m88 casino review are appreciated by clients for providing constructive m88 casino review feasible solutions.
Recent Representative Cases
GuoDa Drugstore introduced international strategic investors with a capital increase of RMB 2.7667 billion
JunHe represented China National Accord Medicines Corporation Ltd. m88 casino review provided legal services for its subsidiary, Sinopharm GuoDa Drugstore Co., Ltd, to receive RMB 2.7 billion from an international strategic investor. This was China’s largest cross-border joint venture in the pharmaceutical retail industry to date. JunHe provided the client with efficient, comprehensive m88 casino review constructive legal services, including designing the transaction structure, assisting in the preparation of the transaction documents, participating in the drafting m88 casino review negotiation of the contracts.
HD Biosciences Co., Ltd. sold its 100% Equity
JunHe assisted HD Biosciences Co., Ltd. in its sale of 100% equity to Wuxi AppTech. Headquartered in Shanghai, HD Biosciences is a leading pre-clinical research m88 casino review development service platform in the industry. Acting as the PRC legal counsel to HD Biosciences m88 casino review its original shareholders, JunHe fully participated in the early discussion, negotiations m88 casino review revision of the transaction documents, as well as the final closing. JunHe assisted the company in arranging m88 casino review coordinating the exit of different shareholders (including Pfizer, Lilly, Morningside Venture Capital, m88 casino review other investors) m88 casino review assisted in hm88 casino reviewling its domestic m88 casino review overseas employee shareholding platform.
JD.com m88 casino review Shanghai Pharma Jointly Build an Online Medical Sale Platform
Shanghai Pharma Health Commerce Co., Ltd. is a medical E-commerce platform developed by Shanghai Pharma. It is a prescription medicine O2O E-commerce platform combining online m88 casino review offline resources, integrating services m88 casino review trades, with “Internet+” as its core concept, to build three online platforms m88 casino review an offline three-tier network. JunHe represented Beijing Jingdong Century Trade Co., Ltd. in the completion of the Series A financing for Shanghai Pharma Health Commerce Co., Ltd.
Series A Financing from Temasek for JW Biotechnology Co. Ltd.
JW Biotechnology Co. Ltd. is an innovative biotechnology company focused on the latest cell-therapy technology. It has introduced the products m88 casino review the technical platform of Juno to China, m88 casino review its CAR-T product JWCAR029 successfully applied for a clinical trial with the former China Food m88 casino review Drug Administration. JunHe represented Temasek in the joint leading investment with Sequoia m88 casino review Yuanming Capital in the USD 90 million Series A financing for JW Biotechnology.
Series B Financing from Temasek for Hangzhou Just Biotherapeutics Inc.
JunHe represented Temasek in the Series B Financing for Hangzhou Just Biotherapeutics Inc., m88 casino review rendered legal services including legal due diligence investigation, reviewing m88 casino review revising the PRC transaction documents, as well as attending negotiations. This project involved a complex dual shareholding structure at both the Cayman level m88 casino review the PRC level m88 casino review was ranked by SINA as one of the top 10 investment m88 casino review financing events in the China healthcare industry in 2017.
PAG’s Investment in Rongchang Pharmaceuticals
JunHe represented PAG in its successful RMB 1 billion financing for Rongchang Pharmaceuticals Ltd. Rongchang Pharmaceuticals Ltd. is a modern pharmaceutical enterprise integrating the R&D, production, m88 casino review sales of modern Chinese medicine m88 casino review biological drugs. Its ADC new anti-tumor drug RC48 was the first ADC drug in China to be approved by the former China Food m88 casino review Drug Administration to enter into clinical trials for human subjects.
